Departing FDA officials say it’s too soon for COVID-19 boosters as White House plans rollout next weeknews2021-09-13T14:13:40+00:00September 13th, 2021|Fierce Pharma|
On heels of one expansion, J&J will pour $176M into another boost for its manufacturing site in Irelandnews2021-09-13T13:58:43+00:00September 13th, 2021|Fierce Pharma|
Novo Nordisk, Roche see outsized threats from U.S. drug pricing talks: analystsnews2021-09-13T13:17:16+00:00September 13th, 2021|Fierce Pharma|
Pharma’s JAK drugs could suffer in rheumatoid arthritis, atopic dermatitis. How do FDA warnings affect other inflammatory uses?news2021-09-13T13:06:28+00:00September 13th, 2021|Fierce Pharma|
From Pfizer to Argenx: A look at potential blockbusters awaiting FDA decisions this yearnews2021-09-13T12:59:53+00:00September 13th, 2021|Fierce Pharma|
‘Schitt’s Creek’ actress stars in bold Evofem DTC campaign for Phexxi birth controlnews2021-09-13T01:34:42+00:00September 13th, 2021|Fierce Pharma|
Bausch pays whopping $300M to settle Glumetza pay-for-delay lawsuit after 800% price hikenews2021-09-10T15:33:59+00:00September 10th, 2021|Fierce Pharma|
AstraZeneca chalks up double win for novel combo of asthma rescue inhalernews2021-09-10T15:23:23+00:00September 10th, 2021|Fierce Pharma|
Pfizer snags world-first atopic dermatitis nod for Xeljanz follow-up Cibinqo amid FDA safety delaynews2021-09-10T13:50:49+00:00September 10th, 2021|Fierce Pharma|
Amgen’s high-profile cancer med Lumakras set for rollout in England thanks to NHS access dealnews2021-09-10T13:45:35+00:00September 10th, 2021|Fierce Pharma|
